Research programme: cell wall synthesis inhibitors - Wyeth

Drug Profile

Research programme: cell wall synthesis inhibitors - Wyeth

Alternative Names: AC 986446; AC98-4

Latest Information Update: 10 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Class Glycopeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Gram-positive infections

Most Recent Events

  • 05 Aug 2004 A preclinical study has been added to the pharmacokinetics section
  • 22 Nov 2002 Preclinical trials in Gram-positive infections in USA (unspecified route)
  • 10 Jan 2002 Preclinical development for Bacterial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top